Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 3 results

ea0037ep120 | Steroids, development and paediatric endocrinology | ECE2015

Six-month interim safety and efficacy of different dose levels of transCon hGH administered once weekly versus standard daily human growth hormone replacement therapy in pre-pubertal children with growth hormone deficiency (GHD)

Chatelain Pierre , Malievsky Oleg , Radziuk Klaudziya , Elsedfy Heba Hassan , Mikhailova Evgenia , Beckert Michael

Background: TransCon hGH is a long-acting prodrug of recombinant human GH (hGH) that releases into the blood compartment fully active unmodified hGH. TransCon hGH was shown in two Phase 1 studies and a Phase 2 study in AGHD to be safe and well tolerated and inducing an IGF-I pharmacodynamic response within the normal range throughout the dosing period. This interim analysis consists of 25 patients completing all 6 months of treatment.Objectives: The obje...
1 shares

ea0041gp139 | Paediatric Endocrinology & Development | ECE2016

2nd year efficacy results of once-weekly administration of CTP-modified human growth hormone (MOD-4023): a phase 2 study in children with growth hormone deficiency

Zelinska Nataliya , Skorodok Julia , Malievsky Oleg , Rosenfeld Ron G , Zadik Zvi , Koren Ronit , Amitzi Leanne , Hershkovitz Oren , Hart Gili , Radziuk Klaudziya

Objective: Growth hormone (GH) replacement therapy currently requires daily injections. This may cause poor compliance, inconvenience and distress for patients. CTP-modified hGH (MOD-4023) has been developed for once-weekly administration in growth hormone deficient (GHD) adults and children. The 18 and 24 month efficacy of once-weekly subcutaneous (SC) administration of MOD-4023 was evaluated in a Phase 2 study in children with GH deficiency.Design and ...
0 shares

ea0041ep845 | Paediatric endocrinology | ECE2016

Safety and tolerability of once-weekly administration of CTP-modified human growth hormone (MOD-4023): phase 2 study in children with growth hormone deficiency

Zelinska Nataliya , Iotova Violeta , Skorodok Julia , Malievsky Oleg , Rosenfeld Ron G. , Zadik Zvi , Koren Ronit , Amitzi Leanne , Hershkovitz Oren , Hart Gili , Radziuk Klaudziya

Objective: Growth hormone (GH) replacement therapy currently requires daily injections. This may cause poor compliance, inconvenience and distress for patients. CTP-modified human GH (MOD-4023) has been developed for once-weekly administration in growth hormone-deficient (GHD) adults and children. In the present Phase 2 study, the safety and tolerability of once-weekly subcutaneous (SC) administration of MOD-4023 were evaluated in GHD children.Design and...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more